Over the past year, a few high profile Alzheimer’s disease human clinical trials have been studying the effectiveness of ‘anti-amyloid therapies’. These therapies are designed to bind to, and remove amyloid plaques in the brain, one of the major pathological markers of Alzheimer ’s disease.
In theory, these therapies sound simple and should be effective but in reality it is proving much more difficult than first thought. So far, the results from human clinical trials have not shown what many people were hoping.
So why are anti-amyloid therapies not working as effectively as we might like and what are the implications for this research?